These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 16546533)
1. Renoprotective effects of renin-angiotensin-system inhibitors. de Zeeuw D; Lewis EJ; Remuzzi G; Brenner BM; Cooper ME Lancet; 2006 Mar; 367(9514):899-900; author reply 900-2. PubMed ID: 16546533 [No Abstract] [Full Text] [Related]
2. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be? Hollenberg NK; Epstein M Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325 [No Abstract] [Full Text] [Related]
3. Renoprotective effects of renin-angiotensin-system inhibitors. Mann JF; Ritz E; Kunz R Lancet; 2006 Mar; 367(9514):900; author reply 900-2. PubMed ID: 16546535 [No Abstract] [Full Text] [Related]
4. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease. Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428 [No Abstract] [Full Text] [Related]
5. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far? Onuigbo MA Int J Clin Pract; 2010 Sep; 64(10):1341-6. PubMed ID: 20716141 [No Abstract] [Full Text] [Related]
6. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Vogt L; Kocks MJ; Laverman GD; Navis G Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515 [TBL] [Abstract][Full Text] [Related]
14. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?]. Luño J; Valderrábano F An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851 [No Abstract] [Full Text] [Related]
15. [Renin inhibition and the kidney]. Ecder T Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474 [TBL] [Abstract][Full Text] [Related]
16. Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. Swift PA; Andrews PA Int J Clin Pract; 2010 Sep; 64(10):1331-3. PubMed ID: 20716138 [No Abstract] [Full Text] [Related]
17. Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Rabelink TJ; Stroes ES; Bouter KP; Morrison P Cardiovasc Res; 1998 Sep; 39(3):543-9. PubMed ID: 9861295 [No Abstract] [Full Text] [Related]
18. Clinical trials in progression of chronic renal failure. Striker GE; Klahr S Adv Intern Med; 1997; 42():555-95. PubMed ID: 9048130 [No Abstract] [Full Text] [Related]
19. ACE inhibitors as a shield against diabetic nephropathy. Materson BJ Arch Intern Med; 1996 Feb; 156(3):239-40. PubMed ID: 8572832 [No Abstract] [Full Text] [Related]
20. Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? Codreanu I; Perico N; Remuzzi G J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S34-8. PubMed ID: 15938031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]